Moderna stock fell Thursday after the Covid vaccine maker reported adjusted income of $6.46 per share on $4.35 billion in second-quarter sales.


On average, analysts polled by FactSet expected Moderna (MRNA) earnings of $5.96 per share and $4.21 billion in sales.

In the year-earlier period, Moderna reported a 31-cent per-share loss and $66 million in sales.

For the year, Moderna said it now expects product sales of $20 billion. Analysts called for adjusted profit of $26.17 a share and $18.77 billion in sales.

Moderna also OK’d a $1 billion stock buyback.

In premarket trading on today’s stock market, Moderna stock fell 5%. Shares are trading at a record high after, earlier this week, Moderna gained a fast track designation for its Respiratory Syncytial Virus vaccine. Like Moderna’s Covid vaccine, the RSV vaccine uses messenger RNA technology.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Horizon Stock Extends Its Record Breakout As Key Drug Recovers From Covid Struggle

BeyondSpring Stock Nearly Triples As Cancer Drug Tops Chemotherapy

See IBD Stock Lists & Get Pass/Fail Ratings For All Your Stocks With IBD Digital

Looking For The Next Big Stock Market Winners? Start With These 3 Steps

Options Trading: How To Start Using Options, How To Manage Risk